AI Article Synopsis
- The study assessed the safety and effectiveness of surgery combined with I seed brachytherapy for treating mucoepidermoid carcinoma (MEC) in pediatric patients with risk factors.
- From September 2002 to January 2012, 24 patients aged 5-16 underwent treatment, and follow-up showed no local recurrence or severe radiation-related complications after their procedures.
- The results indicate that this combined approach is both effective and safe for these patients, but further research with more participants is necessary to confirm these findings.
Article Abstract
Background: This retrospective study was undertaken to analyze the effectiveness and safety of surgery combined with postoperative I seed brachytherapy in the treatment of mucoepidermoid carcinoma (MEC) of the parotid gland with risk factors in pediatric patients.
Procedure: From September 2002 to January 2012, 24 patients, ages 5-16 years (mean, 13.2 years; median, 12.3 years), with MEC of the parotid gland were included. Patients with high risk factors received I seed brachytherapy (median actuarial D90, 97 Gy) within 4 weeks following surgery. Radioactivity was 18.5-33.3 MBq per seed and the prescription dose was 60-120 Gy. Overall and disease-free survival rates, local control rate, and distant metastasis were recorded. Radiation-associated late side effects, including dermatitis, hearing loss, thyroid nodules, and secondary malignancy, were also evaluated.
Results: During the follow-up period of 5-13.4 years (median, 7.2 years), the overall and disease-free survival rates were all 100%. No patients developed local recurrence, regional/distant metastasis, and no severe radiation-associated complications including the second malignancy were noted.
Conclusion: Surgery combined with postoperative I seed brachytherapy is effective and safe in the treatment of MEC of the parotid gland in pediatric patients, with no evidence of severe late radiation-related complications. More patients and longer follow-up data are still needed to prove the efficacy of I brachytherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.26217 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.
Rep Pract Oncol Radiother
December 2024
Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
Article Synopsis
- The study retrospectively evaluated the effectiveness of ultra-low dose rate brachytherapy (uLDR-BT) in 39 patients with unfavorable intermediate risk prostate cancer, despite current guidelines recommending against it due to insufficient evidence.
- Results showed a promising median follow-up of about 56 months, with an 87.02% biochemical failure-free survival rate, indicating uLDR-BT could be a viable treatment option.
- No significant differences in outcomes were observed based on additional risk factors or treatment methods, suggesting that uLDR-BT's effectiveness is consistent across different patient profiles in the intermediate risk category.
Dosimetric verification of point doses for I-125 implants designed by different manufacturers in prostate brachytherapy.
Rep Pract Oncol Radiother
December 2024
Department of Biomedical Physics, Faculty of Physics, Adam Mickiewicz University, Poznań, Poland.
Background: The purpose of this study is to determine the effect of the type of I-125 radioactive source on dose distribution in the planning process of ultra-low dose rate (uLDR) prostate brachytherapy.
Material And Methods: 7 patients who had undergone brachytherapy in our center were included in the study. Dose in five geometrical points were analyzed for 12 types of implants that are available on the market.
Optimized chelator and nanoparticle strategies for high-activity Pd-loaded biodegradable brachytherapy seeds.
EJNMMI Radiopharm Chem
December 2024
The Hevesy Laboratory, DTU Health Technology, Frederiksborgvej 399, 4000, Roskilde, Denmark.
Background: Brachytherapy (BT) is routinely used in the treatment of various cancers. Current BT relies on the placement of large sources of radioactivity at the tumor site, requiring applicators that may cause local traumas and lesions. Further, they suffer from inflexibility in where they can be placed and some sources reside permanently in the body, causing potential long-term discomfort.
View Article and Find Full Text PDFA prospective comparison of implant quality between suture-coated seeds and uncoated seeds in prostate cancer brachytherapy.
J Contemp Brachytherapy
October 2024
Department of Urology, Kurume University School of Medicine, Kurume, Japan.
Purpose: Displacement minimization of seeds is crucial during surgery in brachytherapy; however, only a few reports have compared the operability of different seeds. TheraStrand-SL is a seed, in which TheraAGX100 is wrapped in polyglactin 910 thread, and intra-prostatic displacement is expected to be reduced compared with that of Thera-AGX100, owing to the complex shape of TheraStrand-SL. We conducted a prospective study on the operability and treatment outcomes of TheraAGX100 and TheraStrand-SL placement by a single operator.
View Article and Find Full Text PDFHydrogen-Generating Magnesium Alloy Seed Strand Sensitizes Solid Tumors to Iodine-125 Brachytherapy.
Adv Sci (Weinh)
December 2024
Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Radioactive iodine-125 (I) seed implantation, a brachytherapy technique, effectively kills tumor cells via X-rays and gamma rays, serving as an alternative therapeutic option following the failure of frontline treatments for various solid tumors. However, tumor radioresistance limits its efficacy. Hydrogen gas has anticancer properties and can enhance the efficacy of immunotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!